Moderna and Nebius to report Q3 results: revenue and EPS consensus
Moderna reports on November 6 and Nebius on November 12, both before the market opens. Analyst consensus for revenue and EPS comes from FactSet data.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Moderna (MRNA) will publish its third-quarter 2026 results on November 6, before the market opens. The call is set for 9:30 AM Eastern time (2:30 PM UTC). Analysts expect revenue of 890.25 million USD and earnings per share of (1.10) USD.
Nebius Group N.V. (NBIS) is scheduled to report on November 12, also before the open, at 9:30 AM Eastern time. The revenue estimate stands at 907.20 million USD, with EPS expected at (0.72) USD. The figures come from FactSet, as reported by TradingView.
why it matters
For investors, both reports serve as a gauge for biotech and AI infrastructure names. Actual results against these consensus figures will show how closely analyst expectations matched reality.
market impact
MRNA, NBIS: results set sentiment for biotech and AI infrastructure stocks
tags
instruments
on polymarket
sources
- MRNA Q3'26 Earnings: EPS estimate is (1.10) USD — TradingView, 5 November 2026 at 12:00 UTC
- NBIS Q3'26 Earnings: revenue estimate is 907.20M USD — TradingView, 5 November 2026 at 12:00 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗